Reporting adverse eventsTargeted haemotherapy means that patients are given the correct, safe and effective blood product on time. This requires all the individuals concerned to take their share of responsibility, starting with the blood donor, the blood transfusion services as producers of labile blood products, the transfusion laboratories, the treating doctors and the authorities.
When blood and labile blood products are used, adverse effects must be expected despite all the safety precautions. The systematic compilation and evaluation of data on transfusion reactions, transfusion errors, errors that are discovered and corrected in time (referred to below as “near misses”) and quality defects allows transfusion risks to be identified and safety in the transfusion chain to be increased.
